These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 13563608)

  • 1. The action of glucagon-insulin mixtures in diabetic patients.
    ELRICK H; ARAI Y; HLAD CJ
    J Clin Endocrinol Metab; 1958 Aug; 18(8):825-33. PubMed ID: 13563608
    [No Abstract]   [Full Text] [Related]  

  • 2. The emergency management of the diabetic at home.
    Kidson W
    Med J Aust; 1976 Mar; 1(10):311-2. PubMed ID: 818486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin.
    Gerich JE; Tsalikian E; Lorenzi M; Schneider V; Bohannon NV; Gustafson G; Karam JH
    J Clin Endocrinol Metab; 1975 Dec; 41(06):1178-80. PubMed ID: 1206104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of glucagon to terminate insulin reactions in diabetic children.
    GIBBS GE; EBERS DW; MECKEL BR
    Nebr State Med J; 1958 Feb; 43(2):56-7 passim. PubMed ID: 13504235
    [No Abstract]   [Full Text] [Related]  

  • 5. Insulin and glucagon ratio in the patho-physiology of diabetic ketoacidosis and hyperosmolar hyperglycemic non-ketotic diabetes.
    Wahid M; Naveed AK; Hussain I
    J Coll Physicians Surg Pak; 2006 Jan; 16(1):11-4. PubMed ID: 16441980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inappropriate counter-regulatory hormone levels in insulin treated diabetes.
    Danowski TS; Fisher ER; Kozak W; Bahl VK; Stephan T; Nolan S; Ahmad U
    Behav Neuropsychiatry; 1976 Apr-1977 Mar; 8(1-12):6-15. PubMed ID: 1052263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of glucagon in diabetes.
    Unger RH; Orci L
    Arch Intern Med; 1977 Apr; 137(4):482-91. PubMed ID: 403869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-glucagon antibodies in diabetes mellitus.
    Gergely A; Korányl L; Halmos T; Zsombók M; Péterfy F; Csizér F; Salamon F; Takó J
    Ann Immunol Hung; 1973; 17():231-3. PubMed ID: 4808018
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus.
    Gerich JE; Langlois M; Noacco C; Lorenzi M; Karam JH; Korsham PH
    J Clin Invest; 1976 Aug; 58(2):320-5. PubMed ID: 783198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inappropriate counter-regulatory hormone levels in insulin treated diabetes.
    Danowski TS; Fisher ER; Kozak W; Bahl VK; Stephan T; Nolan S; Ahmad U
    PDM; 1976; 7(9-12)8(1-8):7-16. PubMed ID: 1052833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
    Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
    Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of glucagon in diabetes.
    Unger RH; Orci L
    Compr Ther; 1982 Jan; 8(1):53-9. PubMed ID: 7039948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of diabetes mellitus. New developments and hopes].
    Verspohl EJ
    Med Monatsschr Pharm; 2005 Jun; 28(6):193-202; quiz 203. PubMed ID: 15960421
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of variable mixtures of insulin in the treatment of diabetes in children and adolescents].
    STAFFIERI JJ; CARDONNET LJ
    Pediatr Am; 1951 Apr; 9(4):186-92. PubMed ID: 14875346
    [No Abstract]   [Full Text] [Related]  

  • 15. Potentiation of insulin action: a probable mechanism for the anti-diabetic action of sulfonylurea drugs.
    Lebovitz HE; Feinglos MN; Bucholtz HK; Lebovitz FL
    J Clin Endocrinol Metab; 1977 Sep; 45(3):601-4. PubMed ID: 903405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Artificial pancreas: clinical and therapeutic value in 11 patients (author's transl)].
    Buysschaert M; Lambotte L; Lambert AE
    Nouv Presse Med; 1979 Jul 14-28; 8(32):2597-601. PubMed ID: 386266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future alternative therapies in a quest to halt aberrations in diabetes mellitus.
    Adams G; Wang N; Cui Y
    Biomed Pharmacother; 2005 Jul; 59(6):296-301. PubMed ID: 15939570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and therapeutic use of glucagon].
    Bruni B
    Minerva Med; 1966 Oct; 57(87):3598-605. PubMed ID: 5924394
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications.
    Gerich JE; Lorenzi M; Schneider V; Karam JH; Rivier J; Guillemin R; Forsham PH
    N Engl J Med; 1974 Sep; 291(11):544-7. PubMed ID: 4604408
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of pancreatic islet transplantation on insulin and glucagon levels in diabetic rats.
    Weber CJ; Lerner RL; Felig P; Hardy MA; Reemtsma KB
    Surg Forum; 1975; 26():192-4. PubMed ID: 814633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.